Form 4: NewAmsterdam Pharma CAO Sells Shares Under 10b5-1 Plan

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, sold 18,073 ordinary shares for $25.09 each under a pre-arranged trading plan.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS), sold 18,073 ordinary shares.
• The transaction occurred on September 3, 2025, at a weighted average price of $25.09 per share.
• Following the sale, Ms. Kooij directly beneficially owns 15,000 ordinary shares.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-arranged transaction.

Sentiment

Score: 4

Explanation: The Chief Accounting Officer sold a significant number of shares, which can be perceived as a lack of confidence. However, the transaction was executed under a pre-arranged 10b5-1 plan, mitigating some of the negative sentiment as it suggests a pre-determined financial strategy rather than a reaction to new information.

Positives

• NA

Negatives

• Chief Accounting Officer Louise Frederika Kooij sold 18,073 ordinary shares, reducing her direct beneficial ownership to 15,000 shares. While executed under a Rule 10b5-1 plan, such sales can sometimes be perceived as a signal of reduced confidence by an insider.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the sale by a key executive as a potential signal, though the 10b5-1 plan suggests a pre-determined financial strategy rather than a reaction to new, undisclosed information.

Next Steps

• NA

Key Dates

Keywords

NAMS, NewAmsterdam Pharma, Insider Trading, Form 4, Share Sale, Louise Frederika Kooij, Chief Accounting Officer, 10b5-1 Plan